Results 71 to 80 of about 13,103,023 (178)

Advances in new antivirals for chronic hepatitis B

open access: yesChinese Medical Journal, 2022
. Chronic hepatitis B virus (HBV) infection remains a global health burden. Timely and effective antiviral therapy is beneficial for patients with HBV infection. With existing antiviral drugs, including nucleos(t)ide analogs and interferon-alfa, patients
Yanhua Tang   +5 more
doaj   +1 more source

Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B

open access: yes, 2021
Long-term treatment with nucleos(t)ide analogs (NAs) is the current first line therapy for patients with chronic hepatitis B (CHB), recommended by most of the current guidelines.
Tout I.   +3 more
core   +1 more source

Chronic Hepatitis B in the United States: Current Landscape, Unmet Needs and Future Directions

open access: yesJournal of Viral Hepatitis, Volume 33, Issue 12, December 2026.
ABSTRACT Chronic hepatitis B (CHB) infection represents a major public health challenge in the US, with substantial unmet needs related to timely diagnosis, treatment, monitoring and disease management. This narrative review explores the CHB landscape in the US, including gaps in patient care, the evolving therapeutic landscape, the clinical utility of
Chari Cohen   +3 more
wiley   +1 more source

Practical Considerations for the Design, Conduct, and Reporting of Clinical Pharmacokinetic Drug–Drug Interaction Studies in Drug Development

open access: yesThe Journal of Clinical Pharmacology, Volume 66, Issue 11, November 2026.
Abstract Clinical pharmacokinetic drug–drug interaction (PK‐DDI) studies are frequently required in drug development when metabolizing enzymes and transporters determine pharmacokinetics. Drugs can be victims, perpetrators, or victims and perpetrators, of PK‐DDIs, so the clinical consequences of these interactions, particularly the risks of severe ...
Thomas M. Polasek, John O. Miners
wiley   +1 more source

High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs [PDF]

open access: yes
Sometani E., Hikita H., Murai K., et al. High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs.
Umezawa, Akihiro   +22 more
core   +1 more source

Chronic Hepatitis B Patients Referred for Liver Transplantation After Nucleos(t)ide Analog Cessation

open access: yesJournal of Viral Hepatitis
ABSTRACT Nucleos(t)ide analogs (NAs) provide prolonged viral suppression with favourable clinical outcomes in chronic hepatitis B (CHB) patients. Characterisation of adverse hepatic events after NA cessation leading to liver transplantation (LT) is vital to the improvement of patient management and safety considerations.
Grishma Hirode   +10 more
openaire   +2 more sources

Therapeutic and Prophylactic Agents for Viral Diseases: Current Status, Challenges, and Future Prospects

open access: yesMedComm, Volume 7, Issue 11, November 2026.
This review summarizes current therapeutic and prophylactic strategies for global viral diseases, including vaccines, PrEP, direct‐acting antivirals, and emerging modalities such as CRISPR and siRNA. It highlights their clinical impact, ongoing challenges, and future priorities toward broader protection, improved delivery, and more effective antiviral ...
Sawar Khan   +12 more
wiley   +1 more source

HLA‐A*11:01 Identifies Patients at Risk for Persistent Viraemia and Advanced Fibrosis in HDV Infection

open access: yesAlimentary Pharmacology &Therapeutics, Volume 64, Issue 10, Page 1432-1447, November 2026.
The HLA‐A*11:01 allele is associated with persistent viraemia and advanced liver fibrosis in HDV infection. HLA‐A*11:01 carriers exhibit a reduced T‐cell repertoire, suggesting a narrower T‐cell response to the infection. ABSTRACT Background Hepatitis delta virus (HDV) infection causes the most severe form of viral hepatitis, with highly heterogeneous ...
Maria Francesca Cortese   +11 more
wiley   +1 more source

Demographic characteristics and clinical features of 67 patients with chronic HBV infection following propensity score matching between the 144-week period before the nucleos(t)ide analog switching and at the time of the switching.

open access: yes, 2022
Demographic characteristics and clinical features of 67 patients with chronic HBV infection following propensity score matching between the 144-week period before the nucleos(t)ide analog switching and at the time of the switching.
Shunsuke Yamada (1291752)   +11 more
core   +1 more source

Proteomic Analysis of Serum Extracellular Vesicles Revealed Fibulin‐3 as a Novel Predictive Biomarker for Hepatocellular Carcinoma in Patients With Chronic Hepatitis B

open access: yesHepatology Research, Volume 56, Issue 11, Page 1614-1631, November 2026.
We carried out proteomic analysis of serum extracellular vesicles to identify biomarkers predictive of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B receiving nucleos(t)ide analog therapy. Candidate proteins identified through proteomic analysis were subsequently quantified in serum by ELISA.
Emi Sometani   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy